MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group
Abstract
Prior studies suggest that neuroblastomas that do not accumulate metaiodobenzylguanidine (MIBG) on diagnostic imaging (MIBG non‐avid) may have more favorable features compared with MIBG avid tumors. We compared clinical features, biologic features, and clinical outcomes between patients with MIBG nonavid and MIBG avid neuroblastoma.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 06, 2017
- Source ID
- 10.1002/pbc.26545
Entities
People
- Arlene Naranjo
- Barry L. Shulkin
- Collin Van Ryn
- David L. Baker
- Derek A Oldridge
- Douglas Russ
- Gregory A Yanik
- Harrison Bai
- John M. Maris
- Julie R. Park
- Katherine K. Matthay
- Marguerite Parisi
- Rajen Mody
- Sharon J. Diskin
- Steven G. Dubois
- Susan Kreissman
- Vandana Batra
Organizations
- Alex's Lemonade Stand Foundation
- Duke University Hospital
- Harvard Medical School
- National Institutes of Health
- Princess Margaret Hospital for Children
- St. Jude Children's Research Hospital
- United States Department of Defense
- University of California, San Francisco
- University of Florida
- University of Michigan
- University of Pennsylvania
- University of Washington